Elena Sinauridze

Dr. Elena Sinauridze

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
DKDmitry A. Kireev
Dmitry A. Kireev
NPNadezhda Y. Popenko
Nadezhda Y. Popenko
APAleksei V. Pichugin
Aleksei V. Pichugin
MPMikhail A. Panteleev
Mikhail A. Panteleev
OKOlga V. Krymskaya
Olga V. Krymskaya
ESElena Sinauridze
Elena Sinauridze
Platelet microparticles (PMPs) are small vesicles released from blood platelets upon activation. The procoagulant activity of PMPs has been previously mainly characterized by theirability to bind coagulation factors VIII and Va in reconstructed systems. It can be supposed that PMPs can contribute to the development of thrombotic complications in the pathologic states associated with the increase of their blood concentration. In this study we compared procoagulant properties of calcium ionophore A23187-activated platelets and PMPs using several in-vitro models of hemostasis. Surface densities of phosphatidylserine, CD61, CD62P and factor X bound per surface area unit were determined by flow cytometry. They were 2.7-, 8.4-, 4.3-, and 13-fold higher for PMPs than for activated platelets, respectively. Spatial clot growth rate (Vclot) in the reaction-diffus ion experimental model and endogenous thrombin potential (ETP) were determined in plasma, which was depleted of phospholipid cell surfaces by ultra-centrifugation and supplemented with activated platelets or PMPs at different concentrations. Both Vcllot and ETP rapidly increased with the increase of PMP or platelet concentration until saturation was reached. The plateau values of Vclot and ETP for activated platelets and PMPs were similar. In both assays, the procoagulant activity of one PMP was almost equal to that of one activated platelet despite at least two-orders-of-magnitude difference in their surface areas. This suggests that the PMP surface is approximately 50- to 100-fold more procoagulant than the surface of activated platelets.

1 March 2006 in Biophysical Journal
Verified
Journal Article
Closed access
MPMikhail A. Panteleev
Mikhail A. Panteleev
MOMikhail Ovanesov
Mikhail Ovanesov
DKDmitrii A. Kireev
Dmitrii A. Kireev
ASAlexey M Shibeko
Alexey M Shibeko
ESElena Sinauridze
Elena Sinauridze
FAFazoil I. Ataullakhanov
Fazoil I. Ataullakhanov

18 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LKLarisa Koleva
Larisa Koleva
EBElizaveta Bovt
Elizaveta Bovt
Fazoil I. AtaullakhanovFazoil I. Ataullakhanov
Fazoil I. Ataullakhanov
ESElena Sinauridze
Elena Sinauridze
Drug delivery using natural biological carriers, especially erythrocytes, is a rapidly developing field. Such erythrocytes can act as carriers that prolong the drug’s action due to its gradual release from the carrier; as bioreactors with encapsulated enzymes performing the necessary reactions, while remaining inaccessible to the immune system and plasma proteases; or as a tool for targeted drug delivery to target organs, primarily to cells of the reticuloendothelial system, liver and spleen. To date, erythrocytes have been studied as carriers for a wide range of drugs, such as enzymes, antibiotics, anti-inflammatory, antiviral drugs, etc., and for diagnostic purposes (e.g., magnetic resonance imaging). The review focuses only on drugs loaded inside erythrocytes, defines the main lines of research for erythrocytes with bioactive substances, as well as the advantages and limitations of their application. Particular attention is paid to in vivo studies, opening-up the potential for the clinical use of drugs encapsulated into erythrocytes.

25 October 2011 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
YGYann Godfrin
Yann Godfrin
FHFrançoise Horand
Françoise Horand
RFRobert Franco
Robert Franco
EDEmmanuelle Dufour
Emmanuelle Dufour
Elena KosenkoElena Kosenko
Elena Kosenko
KGKurt C Gunter
Kurt C Gunter
The first human transfusion was performed by the pioneer Dr Jean-Baptiste Denis in France in 1667 and now, three centuries later, around 50 millions blood units are transfused every year, saving mi...

1 August 1994 in Thrombosis Research
Verified
Journal Article
Closed access
FAF.I. Ataullakhanov
F.I. Ataullakhanov
APA.V. Pohilko
A.V. Pohilko
ESElena Sinauridze
Elena Sinauridze
RVR.I. Volkova
R.I. Volkova

18 June 2015 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
MGMarina A. Gracheva
Marina A. Gracheva
EUEvdokiya S. Urnova
Evdokiya S. Urnova
ESElena Sinauridze
Elena Sinauridze
ITIvan D. Tarandovskiy
Ivan D. Tarandovskiy
EOElena B. Orel
Elena B. Orel
ABAnna N. Balandina
Anna N. Balandina
Patients with multiple myeloma (MM) are at increased risk of venous thromboembolism. Therefore, adequate laboratory control of hemostasis and subsequent adjustments of anticoagulant therapy are necessary. We studied hemostasis changes using thromboelastography (TEG), thrombin generation test (TGT) and thrombodynamics (TD) in primary MM patients (PMMpt, n = 25) and patients in remission (RMMpt, n = 34) during blood stem cell (BSC) mobilization. TD and TEG reveal hypercoagulability in PMMpt (*p < 0.05) in relation to healthy volunteers. There was no difference in any of the tests between PMMpt and RMMpt. We detected no heparin effect in 22% of patients one day after the onset of the prophylactic heparin treatment (500 IU/h) during BSC mobilization; tests shifted toward the hypercoagulability in 75% of patients one day after cyclophosphamide (4 g/m2) chemotherapy. Global hemostasis tests were in good agreement with each other, revealed hypercoagulability and heparin “resistance” in patients with MM and may be useful for therapy individualization.